Can adenosine A
6-OHDA-lesioned rat
Adenosine A(2A) receptor antagonists
Dyskinesia
MPTP-treated primate
Motor disability
Parkinson's disease
l-DOPA
Journal
Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
17
07
2020
revised:
11
09
2020
accepted:
15
09
2020
pubmed:
23
12
2020
medline:
12
10
2021
entrez:
22
12
2020
Statut:
ppublish
Résumé
Current treatment of the motor symptoms of Parkinson's disease (PD) focuses on dopamine replacement therapies. While these treatments are initially highly effective, with long-term use and disease progression, the therapeutic response is often limited by the development of motor complications, dopaminergic side effects, and residual unresponsive motor and non-motor symptoms. An alternative or additive treatment approach may be to target non-dopaminergic receptors within the motor control pathways, which function to modulate basal ganglia output. Adenosine A
Identifiants
pubmed: 33349576
pii: S1353-8020(20)30740-9
doi: 10.1016/j.parkreldis.2020.09.026
pii:
doi:
Substances chimiques
Antiparkinson Agents
0
Dopamine Agents
0
Dopamine Agonists
0
Receptor, Adenosine A2A
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S21-S27Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.